Clinical Trial

Safety and Feasibility of Bilateral Striatal Transplantation of DopaCell in Parkinson's Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Dopason is a phase I, open-label, multicenter, single-arm clinical trial designed to evaluate the safety and feasibility of intraputaminal transplantation of human embryonic stem cell-derived dopaminergic progenitor cells (DopaCells) in patients with moderately severe Parkinson's disease.
Protocol Amendment History 1 change
notable Enrollment reduced: 10 -> 6 participants 2026-06-19
Trial Details
NCT Number NCT07572071
Lead Sponsor Royan Institute
Collaborators: Royan AtiTech Pharmed, Shiraz University of Medical Sciences, Iran University of Medical Sciences
Conditions Parkinson Disease (PD)
Enrollment 6 participants
Start Date 2025-08-01
Primary Completion 2028-08-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-18